Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.
The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases.
The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College’s Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.
Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.
The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.
“Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy.” said Professor Girgenrath, the study’s corresponding author. “While most MD treatments are single-target therapies, we’re delving into combinations of different therapies to target multiple pathways.”
The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc).
By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
The Latest Bing News on:
Novel Therapy to Treat Muscular Dystrophy
- Compounds Rectify Hydrogen Sulfide Deficiency, Improve Muscle Function in Duchenne Muscular Dystrophy Modelon February 23, 2021 at 5:00 am
The University of Exeter is spinning out a company to develop mitochondrial sulfide donor small molecule drugs for rare neuromuscular disorders and metabolic diseases.
- New drug molecules hold promise for treating fatal child diseaseon February 22, 2021 at 12:01 pm
Scientists have identified a way to "rescue" muscle cells that have genetically mutated, paving the way to a possible new treatment for rare childhood illness such as Duchenne Muscular Dystrophy (DMD) ...
- For UCLA-based startup, new muscular dystrophy treatment is a personal missionon February 19, 2021 at 11:01 am
In 2008, when Courtney Young was in high school, her cousin, then just a toddler, was diagnosed with Duchenne muscular dystrophy.
- Promising new therapy spares muscle loss in Duchenne muscular dystrophyon February 15, 2021 at 3:59 pm
BUFFALO, N.Y. — A promising therapy for Duchenne muscular dystrophy (DMD) developed by University at Buffalo researchers is moving closer to use in humans. Published in July in Neuromuscular Disorders ...
- Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophyon February 9, 2021 at 2:45 am
Recently, novel genetic approaches have shown ... Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des, Dev Ther. 2017;11:533–45. Echigoya Y, Lim KRQ, Melo D, Bao B, Trieu ...
- Genome editing for Duchenne muscular dystrophy: a glimpse of the future? | Gene Therapyon February 2, 2021 at 10:22 am
Mutations in Dystrophin, one of the largest proteins in the mammalian body, are causative for a severe form of muscle disease, Duchenne Muscular Dystrophy (DMD), affecting not only skeletal muscle ...
- Duchenne Muscular Dystrophy Treatment Market Outlook 2025, Size, Forecasts, Demand, Competitive Analysis, Growth Factors, Key Playerson January 19, 2021 at 10:53 pm
treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness ...
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technologyon January 19, 2021 at 9:49 am
Satellos is a regenerative medicine company dedicated to developing novel therapeutics ... new therapeutic treatment which restores muscle regeneration in Duchenne muscular dystrophy, a lethal ...
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technologyon January 19, 2021 at 8:10 am
Tax Planning Personal Finance Save for College Save for Retirement Invest in Retirement Research Mutual Funds Stocks ETFs Bonds Best Investments ...
- Study could help develop new oral drugs for treating muscular dystrophy, heart failureon January 11, 2021 at 9:21 pm
he has found an exciting and novel path to treating another challenging clinical disorder, muscular dystrophy, and in so doing provided the groundwork to expand this strategy to other disorders." ...
The Latest Google Headlines on:
Novel Therapy to Treat Muscular Dystrophy
The Latest Bing News on:
Muscular dystrophy
- Sarepta wins new drug approval for patients with Duchenne muscular dystrophy, its third marketed treatmenton February 25, 2021 at 11:59 am
The FDA approved a new medicine from Sarepta Therapeutics that treats certain patients with Duchenne muscular dystrophy.
- FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutationon February 25, 2021 at 11:45 am
Today’s approval of Amondys 45 provides a targeted treatment option for Duchenne muscular dystrophy patients with this confirmed mutation.” DMD is a rare genetic disorder characterized by progressive ...
- Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the ...on February 25, 2021 at 11:22 am
AMONDYS 45 is Sarepta’s third RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately -- -- Information for patients ...
- Galesburg FD helps raise $15k+ through virtual fundraising for Muscular Dystrophyon February 23, 2021 at 12:49 pm
GALESBURG, Ill. (KWQC) - Firefighters in Galesburg have helped raise over $15,000 through virtual fundraising for the Muscular Dystrophy Association (MDA). Officials in a release said while COVID has ...
- Compounds Rectify Hydrogen Sulfide Deficiency, Improve Muscle Function in Duchenne Muscular Dystrophy Modelon February 23, 2021 at 5:00 am
The University of Exeter is spinning out a company to develop mitochondrial sulfide donor small molecule drugs for rare neuromuscular disorders and metabolic diseases.
- For UCLA-based startup, new muscular dystrophy treatment is a personal missionon February 19, 2021 at 11:01 am
In 2008, when Courtney Young was in high school, her cousin, then just a toddler, was diagnosed with Duchenne muscular dystrophy.
- Duchenne UK and Parent Project Muscular Dystrophy Award $350,000 to Address Immunological Challenges of Gene Therapy in Duchenne Muscular Dystrophyon February 18, 2021 at 7:00 am
Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), ...
- Duchenne muscular dystrophyon February 18, 2021 at 12:59 am
Duchenne muscular dystrophy is an X-linked progressive, muscle-wasting disease that manifests in childhood as difficulties with movement. This Primer by Aartsma-Rus and colleagues discusses the ...
- Muscular Dystrophy Association to Roll Out the 39th Annual MDA Shamrocks Campaign with Retailers Nationwideon February 16, 2021 at 6:00 am
The Muscular Dystrophy Association (MDA) today launched the nation's largest St. Patrick's Day fundraising program, the 39th annual ...
- SC teacher with muscular dystrophy says returning to classroom without vaccine could be deadlyon February 15, 2021 at 9:57 pm
Lopez said she requested to teach virtually, but because this was denied she’s now on unpaid leave through the Family Medical Leave Act.